Skip to main content

AS/Spondyloarthritis

      Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.
      The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs). This guideline builds on past ACR vaccination guidance, last published in 2021.
      Upadacitinib (Rinvoq) Approved by European Commission for use in adults with active Non-Radiographic Axial Spondyloarthr

      Dr. John Cush RheumNow

      3 years 1 month ago
      Upadacitinib (Rinvoq) Approved by European Commission for use in adults with active Non-Radiographic Axial Spondyloarthritis - 15 mg qd p.o. Approval based on Phase 3 SELECT-AXIS 2 nr-axSpA trial published in Lancet https://t.co/n3Pci5GyoA https://t.co/4aoSOc7xHd
      The janus kinase inhibitor, upadacitinib, has been shown to significantly improve the signs and symptoms of non-radiographic axial spondyloarthritis (nr-AxSpA), extending the efficacy of UPA beyond classic ankylosing spondylitis.
      THe microbiome differs between #AS (n 33) and AS-IBD(59) compared to IBD (105) patients. Study comparing feces & int

      Dr. John Cush RheumNow

      3 years 1 month ago
      THe microbiome differs between #AS (n 33) and AS-IBD(59) compared to IBD (105) patients. Study comparing feces & intesting Bx. Microbiome composition correlated with BASDAI and faecal calprotectin (FCP) levels. https://t.co/D4QCVVDK7G https://t.co/OJkeisycg0
      Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile d

      Dr. John Cush RheumNow

      3 years 1 month ago
      Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders. https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz
      Spinal Findings on MRI May Not Signify SpA

      Research indicates that rheumatologists should be cautious about diagnosing

      Dr. John Cush RheumNow

      3 years 1 month ago
      Spinal Findings on MRI May Not Signify SpA Research indicates that rheumatologists should be cautious about diagnosing SpA on the basis of imaging alone. https://t.co/Z4gox4cx9N https://t.co/PI9BCty8Bx
      Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast.

      Dr. John Cush RheumNow

      3 years 1 month ago
      Rheums: Got a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/QUTIbK3r89 https://t.co/FZcTLREida
      Rheumatologist Survey:
      What do you rely on MOST in diagnosing Still’s disease?
      Sxs? Labs? Both? Criteria? Fever?

      Vot

      Dr. John Cush RheumNow

      3 years 1 month ago
      Rheumatologist Survey: What do you rely on MOST in diagnosing Still’s disease? Sxs? Labs? Both? Criteria? Fever? Vote here: https://t.co/oANKpKqJA5 https://t.co/LIjRSBHNBi
      For about one in six people considered healthy with no reports of back pain, lesions were visible on MRI in the lower spinal column and sacroiliac joint, researchers said -- a sign that rheumatologists should be cautious about diagnosing spondyloarthritis (SpA) on the basis of imaging.
      French registry of IBD due to IL-17 inhib revealed 32 pts- risk of new IBD was low & decreased 2016 to 2019, w/ good

      Dr. John Cush RheumNow

      3 years 2 months ago
      French registry of IBD due to IL-17 inhib revealed 32 pts- risk of new IBD was low & decreased 2016 to 2019, w/ good outcome in 24/31. IBD more common w/ AS (27) vs PsO (4), IBD onse after 4 (1.5–7.5) mos; all cases w/ secukinumab https://t.co/FJAvhmzPkc https://t.co/WSIut9mAEq
      Adding a corticosteroid shot to exercise therapy significantly improved symptoms of chronic Achilles tendinopathy, a 100-person randomized trial found.
      Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of ankylosing spondy

      Dr. John Cush RheumNow

      3 years 2 months ago
      Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of ankylosing spondylitis pts. Note 100% fatigue resolution roughly same vs. placebo @RheumNow #EULAR2022 ABST#POS0305 cc: @doctorRBC : https://t.co/sodp75Nblw
      In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17

      Dr. John Cush RheumNow

      3 years 2 months ago
      In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA. @RheumNow #EULAR2022 ABST#POS0331 cc: @doctorRBC https://t.co/M8YYAOBVat
      ×